Osivax and GC Biopharma unveiled a major partnership focused on developing a more advanced influenza vaccine. The vaccine is set to combine OVX836 and GC FLU. Osivax secured rights to pursue a combined shot.
Older adults must weigh four vaccine decisions this fall, while the federal immunization calendar still lists a 2025 date. Flu and pneumonia deaths have declined for 25 years, but one American age group posted an uptick.